CD26是一种癌症干细胞标志物及治疗靶点。

CD26 a cancer stem cell marker and therapeutic target.

作者信息

Davies Samuel, Beckenkamp Aline, Buffon Andréia

机构信息

Laboratory of Biochemical and Cytological Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.

出版信息

Biomed Pharmacother. 2015 Apr;71:135-8. doi: 10.1016/j.biopha.2015.02.031. Epub 2015 Mar 4.

DOI:10.1016/j.biopha.2015.02.031

PMID:25960228

Abstract

Cancer stem cells (CSCs) comprise a tumor subpopulation responsible for tumor maintenance, resistance to chemotherapy, recurrence and metastasis. The identification of this cell group is very important, but there is still no consensus on its characterization. Several CSC markers have been described, like CD133, CD24, CD44 and ALDH1, but more research to identify new markers to facilitate the identification of CSC in a heterogeneous tumoral mass is required. Thus, this article describes the CD26 expression as a CSC marker and the role that it plays in different types of cancer. CD26 expression correlates with some characteristics of CSCs, like the formation of spheres in vitro, formation of new tumors, and resistance to chemotherapy. CD26 is therefore suggested as an auxiliary marker for CSC in different types of cancer, and as a potential therapeutic target.

摘要

癌症干细胞（CSCs）是肿瘤中的一个亚群，负责肿瘤的维持、化疗抗性、复发和转移。识别这一细胞群体非常重要，但目前对其特征尚无共识。已经描述了几种癌症干细胞标志物，如CD133、CD24、CD44和乙醛脱氢酶1（ALDH1），但仍需要开展更多研究以识别新的标志物，便于在异质性肿瘤块中识别癌症干细胞。因此，本文描述了CD26作为一种癌症干细胞标志物的表达情况及其在不同类型癌症中所起的作用。CD26的表达与癌症干细胞的一些特征相关，如体外成球、形成新肿瘤以及化疗抗性。因此，CD26被建议作为不同类型癌症中癌症干细胞的辅助标志物以及潜在的治疗靶点。